Alvotech Partners With LOTTE Biologics to Expand US Biosimilar Output
Alvotech and LOTTE Biologics announce a long-term manufacturing deal in Syracuse, NY, aimed at boosting global biosimilar production capacity.
Alvotech (NASDAQ: ALVO) and South Korea-based LOTTE Biologics have entered a long-term manufacturing partnership focused on biosimilar drug production at a facility in Syracuse, New York, the companies announced October 6, 2026.
The agreement is part of Alvotech's broader strategy to expand its international manufacturing footprint. The Iceland-headquartered biotechnology firm specializes in the development and production of biosimilar medicines for patients worldwide, while LOTTE Biologics brings dedicated biologics contract manufacturing expertise to the collaboration.
Read more Hilco Real Estate Seeks Buyers for Detroit-Area Rail Properties →
The Syracuse-based arrangement marks a notable investment in U.S. domestic biologics capacity at a time when policymakers and industry stakeholders have placed heightened emphasis on domestic pharmaceutical supply chains. By leveraging LOTTE Biologics' manufacturing capabilities, Alvotech aims to strengthen its ability to supply biosimilar treatments across global markets.
Biosimilars — highly similar versions of already-approved biologic medicines — have become a focal point for efforts to reduce drug costs and broaden patient access. Partnerships that increase manufacturing scale are widely viewed as essential to sustaining a competitive biosimilars market.
Continue reading at GlobeNewswire - Industry News on Financial Services.
